Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Rather than infusional 5 fluorouracil, the use of capecitabine in combination with irinotecan and oxaliplatin (COI) was explored to establish appropriate dose (of irinotecan) and efficacy in terms of response rate and progression-free survival. Toxicity was primarily gastrointestinal and was manageable with no episodes of severe neutropenia or neutropenic fever and response rates were comparable to published phase II reports of FOLFOXIRI.

Testing a New Regimen for Metastatic Colorectal Cancer